Læger, der overvejer samtidig behandling med andre midler, der associeres med myopati, skal omhyggeligt afveje potentielle fordele og risici og monitorere patienterne for eventuelle tegn og symptomer, der tyder på myopati.
Physicians considering concomitant treatment with other agents associated with myopathy should weigh carefully the potential benefits and risks and should monitor patients for any signs or symptoms suggestive of myopathy.